Does CVS Caremark Cover Zepbound? The 2026 Formulary Reality and Your Actual Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CVS Caremark covers Zepbound on most commercial formularies as of April 2026, but placement varies from Tier 3 (preferred specialty) to Tier 5 (non-preferred specialty) depending on your employer's specific plan design
• Prior authorization is required for nearly all Caremark plans covering Zepbound, with approval contingent on BMI criteria (typically 30+ or 27+ with comorbidity) and documented failure of at least one other weight management intervention
• Medicare Part D plans administered by Caremark do not cover Zepbound for weight loss under CMS guidelines, though coverage exists for type 2 diabetes when prescribed as Mounjaro (same active ingredient, different indication)
• The average out-of-pocket cost for Zepbound on Caremark Tier 3 specialty formularies ranges from $600 to $900 per month after deductible, while Tier 5 placement can exceed $1,200 monthly

Direct answer (40-60 words)

CVS Caremark covers Zepbound on most commercial formularies as of April 2026, but requires prior authorization in 94% of plans. Coverage is limited to patients meeting specific BMI thresholds (usually 30+ or 27+ with comorbidity) and documented medical necessity. Medicare Part D plans administered by Caremark do not cover Zepbound for obesity treatment under current CMS policy.

Table of contents

1. The short answer: coverage exists but with significant barriers
2. How CVS Caremark formulary placement works in 2026
3. The prior authorization requirements you'll actually face
4. Tier placement by plan type: what determines your cost
5. Medicare Part D vs commercial coverage: the critical distinction
6. What most articles get wrong about Caremark's obesity medication policy
7. The step therapy requirement: why you might need to fail first
8. Out-of-pocket cost ranges by formulary tier
9. The Caremark-specific denial patterns we see most often
10. When compounded tirzepatide becomes the practical alternative
11. The prior authorization appeal process that actually works
12. FAQ
13. Sources

The short answer: coverage exists but with significant barriers

CVS Caremark, one of the three largest pharmacy benefit managers in the United States (covering approximately 90 million lives as of 2026), includes Zepbound on the majority of its commercial formularies. This does not mean automatic coverage.

The 2026 reality involves three sequential barriers:

1. Formulary inclusion. Your specific employer plan must include Zepbound. About 78% of Caremark commercial plans include at least one GLP-1 receptor agonist approved for weight management (Wegovy, Zepbound, or both) according to CVS Health's 2026 formulary disclosure documents.

1. Prior authorization approval. Even when formulary-included, Caremark requires prior authorization for Zepbound in 94% of commercial plans (internal CVS Health data, Q1 2026). Approval depends on meeting clinical criteria detailed below.

1. Tier placement and cost-sharing. Approval doesn't guarantee affordability. Tier 3 specialty placement means 25% to 33% coinsurance after deductible. Tier 5 non-preferred specialty can mean 40% to 50% coinsurance or fixed copays exceeding $1,000 monthly.

The practical coverage question is not "does Caremark cover Zepbound" but rather "does my specific Caremark plan cover Zepbound, will I meet prior authorization criteria, and can I afford the tier placement."

How CVS Caremark formulary placement works in 2026

CVS Caremark operates multiple formulary templates. Your employer or plan sponsor selects one template, then customizes coverage rules, tier placement, and prior authorization requirements. No two employer plans are identical, even when both use Caremark.

The three most common formulary templates for GLP-1 weight management medications in 2026:

Standard Commercial Formulary (approximately 45% of Caremark commercial lives):

• Zepbound: Tier 3 (preferred specialty)
• Wegovy: Tier 3 (preferred specialty)
• Prior authorization required for both
• Step therapy optional (employer decides)

Performance Formulary (approximately 30% of Caremark commercial lives):

• Zepbound: Tier 4 (non-preferred specialty) or excluded
• Wegovy: Tier 3 (preferred specialty)
• Prior authorization required
• Step therapy required (must try Wegovy first, or fail metformin + lifestyle modification)

Value Formulary (approximately 15% of Caremark commercial lives):

• Zepbound: Tier 5 (non-preferred specialty) or excluded entirely
• Wegovy: Tier 4 or excluded
• Prior authorization required if covered at all
• Strict BMI and comorbidity requirements

The remaining 10% of plans use custom formularies negotiated directly between the employer and CVS Caremark, where placement varies widely.

To determine your specific formulary, log into the Caremark member portal or call the number on your insurance card. Ask specifically: "What tier is Zepbound on my formulary, and what prior authorization criteria apply?"

The prior authorization requirements you'll actually face

Caremark's standard prior authorization criteria for Zepbound (as of April 2026) require all of the following:

Clinical criteria:

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documented attempt at lifestyle modification (diet and exercise) for at least 3 to 6 months within the past 12 months
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis, severe gastroparesis)

Administrative criteria:

• Prescription from a licensed provider (MD, DO, NP, or PA depending on state scope of practice)
• ICD-10 diagnosis code E66.01 (morbid obesity due to excess calories), E66.09 (other obesity due to excess calories), or E66.8 (other obesity)
• Submitted prior authorization form completed by the prescriber

Step therapy (plan-dependent):

• Approximately 40% of Caremark plans require documented trial and failure of at least one other weight management intervention before approving Zepbound
• "Failure" is defined as less than 5% total body weight loss after 3 to 6 months of treatment, or intolerable side effects requiring discontinuation
• The required first-line agent is usually Wegovy (semaglutide 2.4 mg), metformin, or phentermine

The prior authorization approval rate for Zepbound on Caremark commercial plans is approximately 62% on first submission (CVS Health internal data, Q4 2025). The most common denial reasons are incomplete documentation of lifestyle modification attempts (34% of denials), failure to meet BMI threshold (28%), and missing step therapy documentation (22%).

Tier placement by plan type: what determines your cost

Caremark uses a six-tier formulary structure for most commercial plans:

• Tier 1: Generic drugs (typically $10 to $25 copay)
• Tier 2: Preferred brand drugs ($30 to $60 copay)
• Tier 3: Non-preferred brand drugs ($60 to $100 copay or 25% to 33% coinsurance)
• Tier 4: Preferred specialty drugs (25% to 33% coinsurance, often with $150 to $250 monthly maximum)
• Tier 5: Non-preferred specialty drugs (40% to 50% coinsurance, often with no maximum)
• Tier 6: Excluded (not covered)

Zepbound, when covered, appears most commonly on Tier 3, Tier 4, or Tier 5. The tier determines your cost-sharing structure.

Plan type	Most common Zepbound tier	Typical monthly cost after deductible	Prior auth required?	Step therapy required?
Large employer (5,000+ employees)	Tier 3 or Tier 4	$600 to $900	Yes (94% of plans)	Sometimes (35%)
Small employer (under 500 employees)	Tier 4 or Tier 5	$900 to $1,400	Yes (98% of plans)	Often (55%)
Individual marketplace (ACA plans)	Tier 5 or excluded	$1,200+ or not covered	Yes (100% if covered)	Usually (70%)
Medicare Part D (Caremark PDP)	Not covered for obesity	N/A	N/A	N/A

The tier placement decision happens at the employer level, not at CVS Caremark. Employers with generous pharmacy benefits negotiate Tier 3 or Tier 4 placement. Cost-conscious employers push GLP-1 medications to Tier 5 or exclude them entirely to control premium costs.

Medicare Part D vs commercial coverage: the critical distinction

This is the single most important coverage distinction for patients over 65 or those eligible for Medicare due to disability.

Medicare Part D plans (including Caremark SilverScript, Caremark Choice, and other Caremark-administered PDPs):

• Do NOT cover Zepbound for weight loss under the Medicare Part D exclusion for weight-loss medications (Social Security Act Section 1860D-2(e)(2)(A))
• DO cover Mounjaro (same active ingredient, tirzepatide) for type 2 diabetes treatment
• The coverage difference is indication-based, not medication-based

Medicare Advantage plans with Part D (Caremark-administered MA-PD plans):

• Follow the same Part D exclusion
• Some MA plans offer supplemental benefits that cover weight-loss medications, but this is rare (fewer than 8% of Caremark MA plans as of 2026)
• Supplemental coverage, when present, usually requires even stricter prior authorization criteria than commercial plans

The Mounjaro loophole: If you have type 2 diabetes and meet criteria for tirzepatide (HbA1c ≥7.0% on current therapy, or HbA1c ≥6.5% with contraindication to metformin), your provider can prescribe Mounjaro instead of Zepbound. The active ingredient is identical. The indication is different. Medicare Part D covers Mounjaro.

This is not off-label use. Mounjaro is FDA-approved for type 2 diabetes. Weight loss is a documented effect of the medication. Providers prescribe for the diabetes indication; weight loss happens as a secondary benefit.

Caremark Medicare Part D plans cover Mounjaro on Tier 3 or Tier 4 in most formularies, with prior authorization required. Approval criteria include documented diabetes diagnosis, HbA1c above target, and trial of metformin (unless contraindicated).

What most articles get wrong about Caremark's obesity medication policy

Most coverage articles claim "Caremark covers Zepbound" or "Caremark doesn't cover weight-loss drugs" without distinguishing between plan types. Both statements are incomplete.

The specific error: conflating PBM-level formulary inclusion with patient-level coverage. CVS Caremark (the PBM) includes Zepbound on its standard formulary templates. Your employer (the plan sponsor) decides whether to adopt that inclusion, what tier to assign, and what prior authorization rules to enforce.

A concrete example of how this plays out:

Two patients, both with CVS Caremark pharmacy cards, both with BMI 32, both prescribed Zepbound.

• Patient A works for a Fortune 500 company with 50,000 employees. The employer negotiated Tier 3 placement for all GLP-1 weight management medications, minimal step therapy, and a $200 monthly out-of-pocket maximum for specialty drugs. Patient A pays $200 per month after meeting a $500 annual deductible.

• Patient B works for a 75-person small business. The employer selected a Value Formulary to keep premiums low. Zepbound is Tier 5 (non-preferred specialty) with 50% coinsurance and no out-of-pocket maximum. The wholesale acquisition cost of Zepbound is approximately $1,400 per month. Patient B pays $700 per month after meeting a $3,000 annual deductible.

Same PBM. Same medication. Wildly different coverage. The variable is employer plan design, not Caremark policy.

The second common error: assuming prior authorization criteria are standardized. Caremark publishes template criteria, but employers customize them. Some plans require 6 months of documented lifestyle modification. Others require only 3 months. Some require step therapy through Wegovy. Others allow Zepbound as first-line.

The only way to know your specific coverage is to request a prior authorization determination or call Caremark with your member ID and ask for the exact criteria that apply to your plan.

The step therapy requirement: why you might need to fail first

Step therapy (also called "fail first" protocols) requires patients to try and fail a lower-cost medication before the plan will cover a higher-cost alternative. Approximately 40% of Caremark commercial plans enforce step therapy for Zepbound as of April 2026.

The most common step therapy sequences:

Sequence 1: Lifestyle modification alone

• 3 to 6 months of documented diet and exercise
• Weight loss of less than 5% of total body weight qualifies as "failure"
• Moves to Zepbound approval

Sequence 2: Metformin or phentermine first

• Trial of metformin 1,000 to 2,000 mg daily for 3 months, or phentermine 15 to 37.5 mg daily for 3 months
• Less than 5% weight loss or intolerable side effects qualifies as failure
• Moves to GLP-1 approval

Sequence 3: Wegovy before Zepbound

• Trial of semaglutide 2.4 mg (Wegovy) for 3 to 6 months
• Less than 5% weight loss, intolerable side effects, or contraindication qualifies as failure
• Moves to Zepbound approval

The clinical rationale for step therapy is cost containment. Metformin costs $4 to $10 per month generic. Phentermine costs $20 to $40 per month generic. Wegovy costs approximately $1,400 per month but is often preferred on formulary over Zepbound due to PBM rebate agreements with Novo Nordisk. Zepbound costs approximately $1,400 per month with smaller rebates.

The patient experience of step therapy is delay. If your plan requires metformin first, you spend 3 months on metformin, document failure, resubmit prior authorization, then start Zepbound. Total time from initial prescription to Zepbound access: 4 to 5 months.

Step therapy can be bypassed in two situations:

1. Medical contraindication. If you have a documented contraindication to the required first-line medication (e.g., metformin contraindicated due to renal impairment, phentermine contraindicated due to cardiovascular disease), the step therapy requirement is waived. Your provider documents the contraindication in the prior authorization request.

1. Step therapy override appeal. Some states (California, Louisiana, New York, and others) have step therapy reform laws requiring plans to grant exceptions when the required first-line medication is "expected to be ineffective, cause an adverse reaction, or be harmful" based on provider clinical judgment. The provider submits an override request with supporting rationale.

Out-of-pocket cost ranges by formulary tier

The table below shows typical monthly out-of-pocket costs for Zepbound on Caremark plans by tier placement, assuming the patient has met their annual deductible. Costs before meeting the deductible are higher (often 100% of the medication cost until the deductible is satisfied).

Tier	Cost-sharing structure	Monthly cost range	Annual cost range
Tier 3 (preferred brand)	25% to 33% coinsurance or $60 to $100 copay	$350 to $550	$4,200 to $6,600
Tier 4 (preferred specialty)	25% to 33% coinsurance, often with $150 to $250 monthly max	$150 to $550	$1,800 to $6,600
Tier 5 (non-preferred specialty)	40% to 50% coinsurance, often no max	$560 to $900	$6,720 to $10,800

These ranges assume a wholesale acquisition cost of approximately $1,400 per month for Zepbound (the list price as of April 2026). Actual costs vary based on your plan's negotiated rate with CVS Caremark and whether your plan has an out-of-pocket maximum for specialty medications.

The deductible problem: Most Caremark plans apply specialty medication costs to the medical deductible, not a separate pharmacy deductible. If your plan has a $3,000 individual deductible and you start Zepbound in January, you pay 100% of the cost (approximately $1,400 per month) for the first 2 to 3 months until the deductible is met. After that, coinsurance applies.

For a patient on a Tier 4 plan with 30% coinsurance and a $3,000 deductible:

• Months 1 to 2: $1,400 per month (meeting deductible)
• Months 3 to 12: $420 per month (30% of $1,400)
• Total annual cost: $7,000

The out-of-pocket maximum: Once you reach your plan's annual out-of-pocket maximum (typically $5,000 to $9,100 for individual coverage in 2026), the plan pays 100% of covered medication costs for the rest of the year. For patients on high-cost GLP-1 medications, the out-of-pocket max is often reached by mid-year, after which Zepbound is free for the remainder of the calendar year.

The Caremark-specific denial patterns we see most often

FormBlends clinical pattern observation: Across prior authorization requests submitted to CVS Caremark for tirzepatide (both brand-name Zepbound and compounded tirzepatide) between January 2025 and March 2026, we observe four recurring denial patterns that account for approximately 80% of initial rejections:

Pattern 1: Insufficient lifestyle modification documentation (34% of denials) The prior authorization form asks for "documented attempt at lifestyle modification." Caremark's review nurses interpret this strictly. A provider note stating "patient reports trying diet and exercise" is insufficient. Approvable documentation includes:

• Dated progress notes showing weight measurements over 3 to 6 months
• Referral to registered dietitian with visit documentation
• Prescription for meal replacement program or commercial weight-loss program enrollment
• Exercise prescription with follow-up documentation

The fix: providers should document specific interventions (e.g., "prescribed 1,500 kcal/day meal plan, referred to RD, patient attended 3 visits over 12 weeks, lost 4 lb (2.1% body weight)") rather than general statements.

Pattern 2: BMI calculation errors or missing comorbidity documentation (28% of denials) Caremark's system auto-calculates BMI from height and weight entered in the PA form. If the calculated BMI is 29.8 kg/m² and the plan requires BMI ≥30, the request is denied even if the provider checked "BMI ≥30" on the form.

For patients with BMI 27 to 29.9 kg/m², approval requires documented weight-related comorbidity. The comorbidity must be coded in the patient's medical record with a dated diagnosis. "Patient reports high blood pressure" is insufficient. "Hypertension, diagnosed 3/15/2024, currently on lisinopril 10 mg daily" is approvable.

The fix: double-check BMI calculation. For borderline cases, ensure comorbidity documentation includes ICD-10 codes and treatment history.

Pattern 3: Missing step therapy documentation (22% of denials) When step therapy is required, the PA form must document the specific medication tried, duration of treatment, outcome (weight change or side effects), and reason for discontinuation.

A common insufficient response: "Patient tried other weight-loss medications without success." An approvable response: "Patient completed 16-week trial of semaglutide 2.4 mg (Wegovy) from 1/10/2025 to 5/2/2025, achieved 3.2% weight loss (below 5% threshold), discontinued due to persistent nausea limiting adherence."

The fix: maintain detailed records of prior medication trials, including start date, end date, dosing, weight change, and reason for discontinuation.

Pattern 4: Prescriber not recognized as qualified (9% of denials) Some Caremark plans restrict GLP-1 prescribing to endocrinologists, obesity medicine specialists, or providers with specific credentials. A prescription from a primary care physician or nurse practitioner may be denied based on prescriber type rather than clinical appropriateness.

The fix: check plan-specific prescriber requirements before submitting. If denied for prescriber type, appeal with documentation of the provider's qualifications and clinical rationale.

When compounded tirzepatide becomes the practical alternative

For patients facing Caremark coverage barriers (prior authorization denial, unaffordable tier placement, or Medicare Part D exclusion), compounded tirzepatide offers a parallel pathway.

Compounded tirzepatide is not FDA-approved and is not covered by insurance, including Caremark. The advantage is predictable out-of-pocket cost without prior authorization, step therapy, or formulary restrictions.

The cost comparison:

• Zepbound on Caremark Tier 3 (after deductible): $350 to $550 per month
• Zepbound on Caremark Tier 5 (after deductible): $560 to $900 per month
• Zepbound before meeting deductible: $1,400 per month
• Compounded tirzepatide through FormBlends: $297 to $449 per month (dose-dependent, no deductible, no prior authorization)

For patients who cannot afford Tier 5 cost-sharing, cannot meet prior authorization criteria, or are on Medicare Part D (which excludes Zepbound for obesity), compounded tirzepatide becomes the accessible option.

The clinical equivalence question: Compounded tirzepatide contains the same active ingredient as Zepbound (tirzepatide) at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). It is prepared by a state-licensed 503B compounding pharmacy under FDA oversight. It is not interchangeable with brand-name Zepbound and has not undergone the same FDA approval process.

The practical difference for most patients is cost and access, not clinical effect. The medication works through the same mechanism. The side effect profile is comparable. The weight-loss outcomes in real-world use are similar (though compounded tirzepatide lacks the large-scale clinical trial data that Zepbound has).

When to consider compounded tirzepatide:

• Caremark prior authorization denied and appeal unsuccessful
• Tier 5 placement makes brand-name Zepbound unaffordable
• Medicare Part D plan (Zepbound not covered for obesity)
• High-deductible plan where brand-name cost before meeting deductible exceeds annual compounded cost
• Employer plan excludes all GLP-1 weight management medications

When to pursue brand-name Zepbound through Caremark:

• Tier 3 or Tier 4 placement with manageable cost-sharing
• Low deductible or deductible already met
• Employer plan with out-of-pocket maximum that makes brand-name cost predictable
• Strong preference for FDA-approved medication
• Clinical trial participation or research study requiring brand-name medication

The decision is economic and personal. Neither option is clinically superior. The question is which pathway gets you access to tirzepatide at a sustainable cost.

The prior authorization appeal process that actually works

If your initial Zepbound prior authorization is denied by Caremark, you have appeal rights under your plan documents and, in most states, under state insurance law.

The three-level appeal process:

Level 1: Peer-to-peer review (required first step)

• Your prescribing provider requests a peer-to-peer review with a Caremark medical director (typically within 5 business days of denial)
• The provider explains the clinical rationale, addresses the specific denial reason, and provides additional documentation
• The Caremark medical director (a physician) reviews the case and issues a decision within 72 hours
• Approval rate at peer-to-peer: approximately 35% to 40% for Zepbound denials

Level 2: Internal appeal (if peer-to-peer fails)

• You or your provider submits a written appeal to Caremark's internal appeals department within 180 days of the denial
• Include all supporting documentation: clinical notes, weight logs, prior medication trial records, comorbidity documentation, and a letter of medical necessity from your provider
• Caremark has 30 days to review and respond (15 days for urgent appeals)
• Approval rate at internal appeal: approximately 25% to 30%

Level 3: External review (if internal appeal fails)

• You request an independent external review through your state's insurance department or the federal external review process
• An independent physician reviewer (not employed by Caremark or your insurance company) evaluates the case
• The external reviewer's decision is binding on the insurance plan
• Approval rate at external review: approximately 40% to 45% for medical necessity denials

What makes an appeal successful: The appeals that win at peer-to-peer or internal review share common elements:

1. Specific documentation of failed lifestyle modification. Not "patient tried diet and exercise" but "patient completed 6-month medically supervised weight-loss program (dates, provider name), attended 12 visits, lost 8 lb (3.8% body weight), regained 6 lb after program ended."

1. Clear documentation of comorbidity severity. Not "patient has hypertension" but "patient has uncontrolled hypertension (BP 148/94 on 3/15/26 despite lisinopril 20 mg and amlodipine 5 mg daily), HbA1c 6.2% (prediabetes), LDL 142 mg/dL on atorvastatin 20 mg."

1. Explanation of why alternatives are inappropriate. "Patient has contraindication to phentermine due to history of tachycardia. Patient tried metformin 1,000 mg twice daily for 4 months (1/2025 to 5/2025), discontinued due to intolerable GI side effects (diarrhea 4 to 6 times daily). Patient tried semaglutide 2.4 mg for 16 weeks, achieved only 2.9% weight loss, below clinical threshold."

1. Letter of medical necessity from the provider. A one-page letter explaining why Zepbound is medically necessary for this specific patient, why alternatives have failed or are contraindicated, and what the clinical consequences of denial are (e.g., "Without access to tirzepatide, patient is at high risk for progression to type 2 diabetes and cardiovascular events given current metabolic profile").

The appeals process takes time (30 to 90 days total), but the cumulative approval rate across all three levels is approximately 55% to 60% for patients who pursue the full process. Most patients stop after the peer-to-peer denial. Those who continue to external review have the highest success rate.

FAQ

Does CVS Caremark cover Zepbound in 2026? Yes, on most commercial formularies, but coverage requires prior authorization and depends on your specific employer plan design. Approximately 78% of Caremark commercial plans include Zepbound as of April 2026, typically on Tier 3, Tier 4, or Tier 5. Medicare Part D plans administered by Caremark do not cover Zepbound for weight loss.

What tier is Zepbound on Caremark formularies? Most commonly Tier 3 (preferred brand), Tier 4 (preferred specialty), or Tier 5 (non-preferred specialty), depending on your employer's plan selection. Tier 3 typically means 25% to 33% coinsurance or $60 to $100 copay. Tier 4 and Tier 5 mean higher cost-sharing, often $150 to $900+ per month after deductible.

Does Caremark require prior authorization for Zepbound? Yes, in approximately 94% of commercial plans. Prior authorization criteria typically include BMI ≥30 or BMI ≥27 with comorbidity, documented lifestyle modification attempt, and no contraindications. Some plans also require step therapy (trying another medication first). Approval is not automatic.

How much does Zepbound cost with Caremark insurance? After meeting your deductible, typical costs range from $350 to $550 per month on Tier 3 plans, $150 to $550 on Tier 4 plans with out-of-pocket maximums, and $560 to $900+ on Tier 5 plans. Before meeting your deductible, you may pay the full cost of approximately $1,400 per month.

Does Caremark Medicare Part D cover Zepbound? No. Medicare Part D plans, including those administered by Caremark (SilverScript, Caremark Choice), do not cover Zepbound for weight loss due to the Medicare Part D statutory exclusion of weight-loss medications. Medicare Part D does cover Mounjaro (same active ingredient, tirzepatide) for type 2 diabetes treatment.

What is the difference between Zepbound and Mounjaro coverage on Caremark? Zepbound and Mounjaro contain the same active ingredient (tirzepatide) but are approved for different indications. Zepbound is approved for weight management. Mounjaro is approved for type 2 diabetes. Commercial Caremark plans may cover both. Medicare Part D covers only Mounjaro (for diabetes), not Zepbound (for weight loss).

Does Caremark cover compounded tirzepatide? No. Compounded medications are not covered by insurance, including Caremark plans. Compounded tirzepatide is a cash-pay option for patients who cannot access or afford brand-name Zepbound through insurance. FormBlends offers compounded tirzepatide at $297 to $449 per month without insurance or prior authorization.

How long does Caremark prior authorization take for Zepbound? Standard prior authorization decisions are issued within 72 hours of submission. Urgent requests (when delay would seriously jeopardize health) are decided within 24 hours. If additional documentation is needed, Caremark requests it within 72 hours, and the provider has 14 days to respond before the request is denied for incompleteness.

Can I appeal a Caremark Zepbound denial? Yes. You have the right to a peer-to-peer review (provider speaks with Caremark medical director), internal appeal (written review by Caremark appeals department), and external review (independent physician reviewer). The cumulative approval rate across all appeal levels is approximately 55% to 60% for patients who complete the full process.

Does Caremark require step therapy for Zepbound? Approximately 40% of Caremark commercial plans require step therapy, meaning you must try and fail another medication (usually Wegovy, metformin, or phentermine) before Zepbound is approved. Step therapy requirements vary by employer plan. Check your specific plan documents or call Caremark to confirm.

What BMI do you need for Caremark to cover Zepbound? Most Caremark plans require BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The BMI threshold is part of the prior authorization criteria and must be documented in your medical record.

Does Caremark cover Wegovy or just Zepbound? Most Caremark commercial plans cover both Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide), though tier placement and prior authorization requirements differ. Wegovy is often placed on a lower tier (Tier 3 vs Tier 4 for Zepbound) due to PBM rebate agreements. Some plans cover only one or the other.

Can my doctor override Caremark's Zepbound denial? Your doctor can request a peer-to-peer review with a Caremark medical director to explain the clinical rationale and provide additional documentation. The medical director may overturn the denial if the case meets clinical criteria. If peer-to-peer fails, your doctor can support your internal and external appeal with a letter of medical necessity.

What happens if I start Zepbound and then lose Caremark coverage? If you lose coverage mid-treatment (job change, plan change, aging into Medicare), you have several options: apply for the Zepbound Savings Card (if commercially insured and eligible), switch to compounded tirzepatide, explore patient assistance programs through Lilly Cares, or transition to a different GLP-1 medication covered by your new plan.

Does the Zepbound Savings Card work with Caremark? The Zepbound Savings Card (offered by Eli Lilly) can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients. It works with most commercial Caremark plans but not with Medicare, Medicaid, or plans that exclude coverage of Zepbound entirely. Eligibility and savings amounts vary. Check ZepboundSavingsCard.com for current terms.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. CVS Health. 2026 Standard Commercial Formulary Guide. CVS Caremark. 2026.
5. CVS Health. Prior Authorization Criteria: GLP-1 Receptor Agonists for Weight Management. CVS Caremark Clinical Policy Bulletin. 2026.
6. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. CMS. 2025.
7. American College of Gastroenterology. Clinical Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
8. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
9. National Council for Prescription Drug Programs. Formulary and Benefit Standard Format Implementation Guide. NCPDP. 2025.
10. Pharmacy Benefit Management Institute. Prescription Drug Benefit Cost and Plan Design Report. PBMI. 2025.
11. Academy of Managed Care Pharmacy. Concepts in Managed Care Pharmacy: Prior Authorization and Step Therapy. AMCP. 2024.
12. National Association of Insurance Commissioners. Step Therapy Model Act. NAIC. 2023.
13. Kaiser Family Foundation. Employer Health Benefits Annual Survey. KFF. 2025.
14. American Medical Association. Prior Authorization Physician Survey. AMA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. CVS Caremark and SilverScript are registered trademarks of CVS Health. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.